Therapeutic Asset Ratings
138 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Arc-T Cells
Myelodysplastic Syndromes
Arcellx, Inc.
P1
C
(37)
aur103
Myelodysplastic Syndromes
Aurigene Discovery Technologies Limited
P1
C
(37)
cc-91633
Myelodysplastic Syndromes
Celgene
P1
C
(37)
cd33 fpbmc
Myelodysplastic Syndromes
University of Virginia
P1
C
(37)
cd4+cd25+ regulatory t cells
Myelodysplastic Syndromes
Stanford University
P1
C
(37)
Ciml-Nk Cells
Myelodysplastic Syndromes
Dana-Farber Cancer Institute
P1
C
(37)
Cytokine Induced Memory-Like Natural Killer Cells
Myelodysplastic Syndromes
Dana-Farber Cancer Institute
P1
C
(37)
Danvatirsen
Myelodysplastic Syndromes
Montefiore Medical Center
P1
C
(37)
Defactinib
Myelodysplastic Syndromes
Clinical Hub for Interventional Research (CHOIR)
P1
C
(37)
dsp107
Myelodysplastic Syndromes
Kahr Medical
P1
C
(37)
Eagd T-Cell Infusion
Myelodysplastic Syndromes
University of Kansas Medical Center
P1
C
(37)
fxs0683
Myelodysplastic Syndromes
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
P1
C
(37)
Glb-001
Myelodysplastic Syndromes
Hangzhou GluBio Pharmaceutical Co., Ltd.
P1
C
(37)
Gtb-360
Myelodysplastic Syndromes
Masonic Cancer Center, University of Minnesota
P1
C
(37)
Immunoglobulin G4, anti-(human CD3 antigen) (recombinant human monoclonal JNJ-75348780 ?4-chain), disulfide with recombinant human monoclonal JNJ-75348780 ? chain, (229?126?),(232?129?)-bis(disulfide) with immunoglobulin, anti-(human sialic acid-binding Ig-like lectin 2) (recombinant human single-domain VHH fragment)
Myelodysplastic Syndromes
Janssen Research & Development, LLC
P1
C
(37)
Jnj-54179060
Myelodysplastic Syndromes
Janssen Research & Development, LLC
P1
C
(37)
Jnj-64264681
Myelodysplastic Syndromes
Janssen Research & Development, LLC
P1
C
(37)
Jnj-70218902
Myelodysplastic Syndromes
Janssen Research & Development, LLC
P1
C
(37)
Jnj-80948543
Myelodysplastic Syndromes
Janssen Research & Development, LLC
P1
C
(37)
Jnj-87801493
Myelodysplastic Syndromes
Janssen Research & Development, LLC
P1
C
(37)
lp-108
Myelodysplastic Syndromes
Guangzhou Lupeng Pharmaceutical Company LTD.
P1
C
(37)
mgd024
Myelodysplastic Syndromes
MacroGenics
P1
C
(37)
Orcagraft
Myelodysplastic Syndromes
Orca Biosystems, Inc.
P1
C
(37)
Orca-Q
Myelodysplastic Syndromes
Orca Biosystems, Inc.
P1
C
(37)
Prgn-3006 T Cells
Myelodysplastic Syndromes
Precigen, Inc
P1
C
(37)
Showing 101 to 125 of 138 assets
Previous
Page 5 of 6
Next
